| __timestamp | Bausch Health Companies Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 165772000 |
| Thursday, January 1, 2015 | 2682700000 | 196614000 |
| Friday, January 1, 2016 | 2810000000 | 303251000 |
| Sunday, January 1, 2017 | 2582000000 | 366406000 |
| Monday, January 1, 2018 | 2473000000 | 434407000 |
| Tuesday, January 1, 2019 | 2554000000 | 468711000 |
| Wednesday, January 1, 2020 | 2367000000 | 516922000 |
| Friday, January 1, 2021 | 2624000000 | 739560000 |
| Saturday, January 1, 2022 | 2625000000 | 1002140000 |
| Sunday, January 1, 2023 | 2917000000 | 1161300000 |
| Monday, January 1, 2024 | 1242157000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Incyte Corporation and Bausch Health Companies Inc. over the past decade.
From 2014 to 2023, Bausch Health consistently reported higher SG&A expenses, peaking at approximately $2.9 billion in 2023. This represents a 44% increase from their 2014 figures. In contrast, Incyte Corporation's SG&A expenses grew significantly, with a 600% increase from 2014 to 2023, reaching around $1.16 billion.
The data suggests Bausch Health's steady investment in SG&A reflects a mature market strategy, while Incyte's rapid increase indicates aggressive expansion efforts. These trends highlight differing approaches to market positioning and operational scaling within the industry.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Bausch Health Companies Inc.
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Incyte Corporation
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Biogen Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Incyte Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Incyte Corporation and Geron Corporation
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
MorphoSys AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Merus N.V.: SG&A Expense Trends
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights